Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update - Slideshow
The Big Market Report Take
Summary unavailable.
Not financial advice. The Big Market Report aggregates news for informational purposes only. Nothing on this site constitutes investment advice. Equities and other securities are subject to market risk. Always do your own research and consult a qualified financial advisor before making any investment decisions. Full disclaimer →
Never miss a story
More from this section
The Best High-Yield Financial Stock to Invest $1,000 in Right NowThe Motley Fool59m ago
The Kestra Director Who Built and Sold a Device Company Keeps Buying StockThe Motley Fool1h ago- 3 Reasons Stocks Might Crash Under Trump in 2026The Motley Fool1h ago
Here's How Claiming Social Security at 62 Affects Your Monthly Income for LifeThe Motley Fool1h ago